Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003741 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003741 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center.
The verdict
NCT00003741, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients with refractory anaplastic large cell lymphoma or Hodgkin's lymphoma.
Interventions
- BIOLOGICAL monoclonal antibody HeFi-1
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003741
The ClinicalTrials.gov registry entry for NCT00003741 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which monoclonal antibody HeFi-1 is the first listed.
NCT00003741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003741 about?
NCT00003741 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients with refractory anaplastic large cell lympho...
What is the current status of trial NCT00003741?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-02. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00003741?
The interventions under investigation include: monoclonal antibody HeFi-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003741?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.